Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2251
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$138.50
Sist synkronisert: 2026-10-20
Markedsverdi
$8.96B
Endring (1 dag)
3.02%
Endring (1 år)
84.67%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Inntekter for Protagonist Therapeutics, Inc. (PTGX)
Inntekter i Jun 2026 TTM: $84.34M
Ifølge Protagonist Therapeutics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $84.34M. I 2023 hadde selskapet et resultat på $-78.96M, en økning sammenlignet med resultatet i 2022, som var $-127.39M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Protagonist Therapeutics, Inc. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $84.34M | -69.82% |
| 2024 | $279.41M | -453.88% |
| 2023 | $-78.96M | -38.02% |
| 2022 | $-127.39M | 1.47% |
| 2021 | $-125.55M | 93.62% |
| 2020 | $-64.85M | -16.74% |
| 2019 | $-77.88M | 96.05% |
| 2018 | $-39.72M | 7.48% |
| 2017 | $-36.96M | -0.59% |
| 2016 | $-37.18M | 150.22% |
| 2015 | $-14.86M | 34.19% |
| 2014 | $-11.07M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | 6,154.48% |
US
|
|
| $-3.09B | -3,760.27% |
US
|
|
| $-4.02B | -4,862.02% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 2,212.90% |
NL
|
